SoucekL, WhitfieldJ, MartinsCP, et al.Modelling Myc inhibition as a cancer therapy. Nature, 2008; 455:679–683.
2.
Han HJain AD, Truica MI, et al. Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy. Cancer Cell, 2019; 36:483–497.
3.
BeaulieuME, CastilloF, SoucekL. Structural and biophysical insights into the function of the intrinsically disordered myc oncoprotein. Cells, 2020; 9(4):1–27.
4.
GarraldaE, BeaulieuM-E, MorenoV, et al.MYC-targeting by OMO-103 in solid tumours: A phase 1 trial. Nat Med, 2024 (in press).
5.
CalvisC, BeierA, FeichtingerM, et al.IDP-121, a first in class staple peptide targeting c-MYC. Cancer Res, 2021; 81:2471.
6.
LiZ, HuangY, HungTI, et al.MYC-targeting inhibitors generated from a stereodiversified bicyclic peptide library. J Am Chem Soc, 2024; 146:1356–1363.
7.
UllrichS, NitscheC. Bicyclic peptides: Paving the road for therapeutics of the future. Pept Sci, 2023; 1–15.
8.
QianZ, RhodesCA, McCroskeyLC, et al.Enhancing the cell permeability and metabolic stability of peptidyl drugs by reversible bicyclization. Angew Chem, 2017; 56:1525–1529.
9.
LiZ, ShaoS, RenX, et al.Construction of a sequenceable protein mimetic peptide library with a true 3D diversifiable chemical space. J Am Chem Soc, 2018; 44:14552–14556.
